ADC Products

ADC Therapeutics is a commercial-stage biotechnology company specializing in the development of highly targeted antibody-drug conjugates (ADCs) for the treatment of hematological malignancies and solid tumors. The company's proprietary platform utilizes pyrrolobenzodiazepine (PBD) dimers, which are potent cytotoxic payloads designed to bind to the minor groove of DNA and avoid the DNA repair mechanisms that often lead to drug resistance. Its lead product, Zynlonta (loncastuximab tesirine-lpyl), is an FDA-approved ADC targeting CD19 for patients with relapsed or refractory large B-cell lymphoma. ADC Therapeutics continues to advance a diverse pipeline of clinical and preclinical candidates, leveraging its expertise in linker-payload technology and antibody engineering to address unmet medical needs in oncology.